Loading market observation…
Loading research…
Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.
Latest observed price
$62.62
Session change unavailableStatus checked Oct 24, 2026, 11:35 PM · America/New_York
Observed Sep 21, 2026, 8:00 PM UTC · Last available price
The latest observed price above is market data. Forecast starting prices are issuance-frozen values and are labelled separately in Model Forecast below.
Review the dated model forecast and five-factor Scorecard for BMY. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.
Lower Estimate (P10)
$43.03
-31.3%
Median Estimate (P50)
$66.19
+5.7% from starting price
Upper Estimate (P90)
$88.29
+41.0%
The estimate uses its dated starting price. It does not predict returns from today’s quote.
View forecast details, dates and available rangesLoading research…
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Loading research…
Risk / safety methodology: Safety describes recent price swings and distance from a recent high alongside cash flow and profitability. It is not a credit rating or a promise of protection from loss.
Multi-factor scoring at a glance
Individual factor readings · Shading shows available dimensions only. Overall requires all five scores and a comparable peer group.
A combined view of Value, Quality, Growth, Safety and Momentum. Review the factor breakdown alongside the total.
Scores and key insights for each dimension
How its fundamental growth measures compare.
How its valuation measures compare with the group.
How its profitability and operating quality compare.
How its price swings, distance from a recent high, cash flow and profitability compare.
How its recent price-trend measures compare.
All scores in this Scorecard describe relative characteristics as of the shown date, using historical market data and reported company information; higher scores on the 0–100 scale indicate more favorable characteristics in the relevant comparison group, and none forecasts future performance.
Higher scores indicate higher relative readings.
Upgrade to Pro to explore this analysis.
Scores are relative comparisons, not absolute grades: companies with different coverage may be scored on different inputs. Peer positions and input coverage can differ by factor; use the displayed comparison group and date when comparing readings. An 80 is not an 80% chance of a price rise. These scores are not price forecasts or recommendations.
The rank with complete inputs compares only companies with every input for that factor, using the issued scores. Equal partial coverage percentages do not establish matching inputs. Current stockwide snapshots use matching input groups; older snapshots may use a smaller fixed group. Scores do not separately adjust for industry or company size. Growth readings do not establish multi-year persistence or separate share-count effects from EPS growth. Scores are independent of the selected forecast horizon.
Latest update · 2026-09-21
View Plans to read the previous successful update.
Previous update means the last successfully published update, including across weekends and market holidays. The Analysis tab keeps the information used in its latest report.
Open a ready-made screen, review its filters and adapt it to your questions.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
Upgrade to Plus or Pro to explore this analysis.
A comparison appears after a previous update is available.
Upgrade to Plus or Pro to explore this analysis.
Start with profit, cash generation and financial flexibility. Scores describe relative characteristics and do not predict returns.
Market observations, financial reporting periods and report dates can differ. Each measure shows its own period.
Compare company metrics only when their currency, observation date and reporting periods agree. Similar companies are starting points for research, not substitutes for each other.
Upgrade to Plus or Pro to explore this analysis.
Economic observations provide background. Observation periods and release dates can differ; these readings do not establish a company-specific effect.
Unavailable
Reported ownership and transaction amounts are disclosure observations, not investment instructions. Filing dates can lag the transaction date.
Unavailable
New filing entries since the previous update. An entry does not establish a change in the document's contents.
Keep your own questions and observations with this company.
Sign in to save a noteExplore related companies in our coverage. Open a stock for its full forecast and Scorecard.
PFE
Latest observed price
$27.74
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$29.02
+4.6%
From $27.74 starting price
Target Sep 21, 2027
Overall Score
ModerateForecast basis Sep 21, 2026
Score date Sep 22, 2026
SNY
Latest observed price
$42.50
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$45.04
+6.0%
From $42.50 starting price
Target Sep 21, 2027
Overall Score
UnavailableForecast basis Sep 21, 2026
Score date —
ZTS
Latest observed price
$71.33
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$76.86
+7.7%
From $71.33 starting price
Target Sep 21, 2027
Overall Score
ModerateForecast basis Sep 21, 2026
Score date Sep 22, 2026
LLY
Latest observed price
$1,164.41
Observed
Sep 21, 2026
12-month forecast
Median (P50)
$1,267.26
+8.8%
From $1,164.41 starting price
Target Sep 21, 2027
Overall Score
StrongForecast basis Sep 21, 2026
Score date Sep 22, 2026
12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.
